Stockscreener 앱 받기
563.16
2.53%
13.88
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $547.00 by Analysts at Bank of America - MarketBeat
Canaccord Genuity Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $150.00 - MarketBeat
GKV Capital Management Co. Inc. Purchases Shares of 3,835 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Evergreen Capital Management LLC Acquires 3,030 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Marshall Wace LLP Has $90.75 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Savvy Advisors Inc. Purchases New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ExodusPoint Capital Management LP Sells 7,047 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Reuters
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application | REGN Stock News - GuruFocus
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application - The Manila Times
FDA Decision: EYLEA HD Extended Dosing Rejected But Current 16-Week Regimen Stays Approved - Stock Titan
Rockefeller Capital Management L.P. Sells 3,260 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria - marketscreener.com
The Goldman Sachs Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $917.00 - MarketBeat
Seven Up For Sanofi and Regeneron With Dupixent CSU Approval - insights.citeline.com
Regeneron (REGN) Secures FDA Priority Review for EYLEA HD Injection | REGN Stock News - GuruFocus
FDA Approves Dupixent for Chronic Spontaneous Urticaria Treatment: Regeneron (REGN) | REGN Stock News - GuruFocus
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) - The Manila Times
Press Release: Dupixent approved in the US as the first new - GlobeNewswire
Breakthrough: FDA Clears Dupixent for 300,000 Chronic Urticaria Patients After Decade-Long Wait - Stock Titan
Aware Super Pty Ltd as trustee of Aware Super Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sagespring Wealth Partners LLC Purchases Shares of 536 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion - Benzinga
FDA to review Regeneron’s sBLA for aflibercept injection 8mg - Yahoo Finance
Regeneron (REGN) Awaits FDA Decision on Eylea HD Expansion - GuruFocus
Regeneron says Eylea HD under FDA review for label expansion - Seeking Alpha
Biocon Biologics deal for Yesafili commercialization - The Pharma Letter
Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts - Benzinga
Regeneron Says Application for Expanded Use of Eylea Accepted for FDA Priority Review - marketscreener.com
Regeneron announces FDA accepted Priority Review sBLA for EYELEA HD - TipRanks
Regeneron (REGN) Advances with Priority Review for EYLEA HD by FDA | REGN Stock News - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Conservative Growth Prospects | REGN Stock News - GuruFocus
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indicatio - GuruFocus
FDA reviews new EYLEA HD injection for less frequent dosing - Investing.com
Regeneron Announces FDA Acceptance of Priority Review for EYLEA HD® Supplemental Application for Retinal Vein Occlusion Treatment - Nasdaq
Dodge & Cox Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Guggenheim Capital LLC - MarketBeat
Jump Financial LLC Buys 17,586 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Eylea Hd® (Aflibercept) Injection 8 Mg Sbla Accepted For FDA Priority Review - MarketScreener
EYLEA HD's Breakthrough RVO Treatment Could Cut Injection Frequency by 50% as FDA Grants Priority Review - Stock Titan
Regeneron (REGN) Target Price Cut by BofA Amid Earnings Concerns | REGN Stock News - GuruFocus
XTX Topco Ltd Buys 1,274 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Canada Post Corp Registered Pension Plan Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Coign Capital Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's (REGN) Odronextamab Gains FDA Orphan Designation for Rare Lymphoma Treatment | REGN Stock News - GuruFocus
ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Demand for Novel Lipid-Lowering Therapies | DelveInsight - Yahoo Finance
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA - Ophthalmology Times
What to Expect From Regeneron's Next Quarterly Earnings Report - MSN
Complement Inhibitors Market 2024 Edition: Size, Share, Trends - openPR.com
Regeneron: Still A Biotech Juggernaut (NASDAQ:REGN) - Seeking Alpha
Heritage Trust Co Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
F M Investments LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
What To Expect From Regeneron's Next Quarterly Earnings Report - Barchart.com
Biocon achieves settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times
Taurus Asset Management LLC Acquires 1,130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US - Medical Dialogues
Neutralizing Antibody Market Set to Witness Significant Growth - openPR.com
Biocon Biologics' Yesafili to enter US market, following agreement with Regeneron - timesofindia.indiatimes.com
Kennedy Capital Management LLC Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers - The Globe and Mail
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $917.00 by Analysts at The Goldman Sachs Group - Defense World
1.47%
자본화:
|
볼륨(24시간):